Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.
Institutional and Insider Ownership
40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 10.7% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Unicycive Therapeutics and 60 Degrees Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Unicycive Therapeutics | N/A | N/A | -$36.73 million | ($4.12) | -0.98 |
| 60 Degrees Pharmaceuticals | $641,412.00 | 8.70 | -$7.95 million | ($50.41) | -0.03 |
60 Degrees Pharmaceuticals has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Unicycive Therapeutics has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.73, meaning that its share price is 173% more volatile than the S&P 500.
Profitability
This table compares Unicycive Therapeutics and 60 Degrees Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Unicycive Therapeutics | N/A | -243.13% | -119.46% |
| 60 Degrees Pharmaceuticals | -976.86% | N/A | -133.88% |
Analyst Recommendations
This is a summary of recent recommendations for Unicycive Therapeutics and 60 Degrees Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Unicycive Therapeutics | 0 | 0 | 2 | 1 | 3.33 |
| 60 Degrees Pharmaceuticals | 0 | 1 | 1 | 0 | 2.50 |
Unicycive Therapeutics currently has a consensus price target of $57.00, indicating a potential upside of 1,317.91%. 60 Degrees Pharmaceuticals has a consensus price target of $3.00, indicating a potential upside of 120.59%. Given Unicycive Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Unicycive Therapeutics is more favorable than 60 Degrees Pharmaceuticals.
Summary
Unicycive Therapeutics beats 60 Degrees Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
